来凯医药-B(02105.HK)：LAE103的新药临床试验已获得美国食品药品监督管理局批准

Group 1 - The core point of the article is that Lai Kai Pharmaceutical-B (02105.HK) has received FDA approval for the IND of LAE103, which is aimed at providing precision treatment for patients with metabolic diseases who require new therapeutic options [1] Group 2 - The company is focused on developing innovative treatment solutions for metabolic diseases [1]